Condylomata Acuminata Clinical Trial
Official title:
A Phase 2, Open-label, Safety, Tolerability, and Efficacy Trial of a Botanical Drug at One Dose Level for the Treatment of External Condylomata Acuminata (Genital Warts) in Adult Immunocompetent Subjects
This trial will be a phase 2, open-label, study to evaluate the safety, tolerability, and efficacy of VIR007 when administered topically for up to 60 days to adults between the ages of 18 to 65 years with a clinical diagnosis of external condylomata acuminata.
This trial will be a phase 2, open-label, study to evaluate the safety, tolerability, and efficacy of VIR007 when administered topically for up to 60 days to adults between the ages of 18 to 65 years with a clinical diagnosis of external condylomata acuminata. Subjects will enter the Screening Period once the informed consent process has been completed. Subjects with a clinical diagnosis of external condylomata acuminata and who meet all inclusion and none of the exclusion criteria will be enrolled. Once subject eligibility is confirmed and the screening procedures completed, the subject will start the Treatment Period of the study. All enrolled subjects will receive VIR007 (cream containing 10% EISO) with the first dose applied topically during Visit 1 (Day 1). Subjects will be instructed on how to apply the study medication twice daily for up to 60 days or until the Investigator determines the lesions have cleared. Subjects will return to the clinic for study-related assessments on Study Days 7, 14, 28, 42 and a Final Study Visit on Day 60. 30 days following complete resolution, as determined by the study investigator, or, on Study Day 90, subjects will receive a follow-up telephone call and be queried regarding condition status since study completion. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
| Completed |
NCT00090285 -
An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)
|
Phase 3 | |
| Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
| Completed |
NCT02015260 -
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
|
Phase 2 | |
| Active, not recruiting |
NCT05056402 -
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
|
Phase 3 | |
| Withdrawn |
NCT00365443 -
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
|
Phase 2 | |
| Not yet recruiting |
NCT01483794 -
Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile
|
N/A | |
| Completed |
NCT03935204 -
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 2 | |
| Completed |
NCT02405520 -
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
|
Phase 1 | |
| Active, not recruiting |
NCT02710851 -
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
|
Phase 2 | |
| Completed |
NCT04782895 -
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
|
Phase 3 | |
| Completed |
NCT03546842 -
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
|
Phase 3 | |
| Completed |
NCT03981822 -
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
|
Phase 2 | |
| Recruiting |
NCT03158480 -
Safety and Efficacy of Immune Therapy for Condyloma
|
N/A | |
| Completed |
NCT01598779 -
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
|
N/A | |
| Completed |
NCT00449982 -
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
|
Phase 3 | |
| Completed |
NCT03813940 -
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 1 | |
| Not yet recruiting |
NCT06197802 -
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
|
||
| Completed |
NCT01532102 -
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06297187 -
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
|